PMID- 35778343
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20220803
IS  - 2255-534X (Electronic)
IS  - 2255-534X (Linking)
VI  - 87
IP  - 3
DP  - 2022 Jul-Sep
TI  - Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: 
      Is it possible to change that paradigm using modern molecular methods?
PG  - 330-341
LID - S2255-534X(22)00065-2 [pii]
LID - 10.1016/j.rgmxen.2022.06.003 [doi]
AB  - Helicobacter pylori (H. pylori) infection is the most widespread 
      infectious-contagious disease worldwide, reaching a prevalence of 50-80% in 
      developing countries. Chronic infection is considered the main cause of chronic 
      gastritis and has been related to other diseases, such as peptic ulcer, gastric 
      mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The most common 
      treatment is with eradication regimens that utilize three or four drugs, 
      including a proton pump inhibitor (PPI) and the antibiotics, clarithromycin and 
      amoxycillin or metronidazole. Empiric antibiotic use for eradicating the 
      bacterium has led to a growing resistance to those drugs, reducing regimen 
      efficacy and increasing costs for both the patient and the healthcare sector. In 
      such a context, the development of noninvasive next-generation molecular methods 
      holds the promise of revolutionizing the treatment of H. pylori. The genotypic 
      and phenotypic detection of the resistance of the bacterium to antibiotics 
      enables personalized treatment regimens to be provided, reducing costs and 
      implementing an antibiotic stewardship program. The aims of the present narrative 
      review were to analyze and compare the traditional and next-generation methods 
      for diagnosing H. pylori, explain the different factors associated with 
      eradication failure, and emphasize the impact of the increasing antibiotic 
      resistance on the reversal and prevention of H. pylori-associated diseases.
CI  - Copyright (c) 2022 Asociacion Mexicana de Gastroenterologia. Published by Masson 
      Doyma Mexico S.A. All rights reserved.
FAU - Garrido-Trevino, L F
AU  - Garrido-Trevino LF
AD  - Instituto de Salud Digestiva, Tecnologico de Monterrey, Escuela de Medicina y 
      Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico.
FAU - Lopez-Martinez, M
AU  - Lopez-Martinez M
AD  - Instituto de Salud Digestiva, Tecnologico de Monterrey, Escuela de Medicina y 
      Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico.
FAU - Flores-Hinojosa, J A
AU  - Flores-Hinojosa JA
AD  - Instituto de Salud Digestiva, Tecnologico de Monterrey, Escuela de Medicina y 
      Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico.
FAU - Tijerina-Rodriguez, L
AU  - Tijerina-Rodriguez L
AD  - Laboratorio Hospital San Jose TecSalud, Monterrey, Nuevo Leon, Mexico.
FAU - Bosques-Padilla, F
AU  - Bosques-Padilla F
AD  - Instituto de Salud Digestiva, Tecnologico de Monterrey, Escuela de Medicina y 
      Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico; Hospital Universitario, 
      Departamento de Gastroenterologia, Universidad Autonoma de Nuevo Leon, Monterrey, 
      Nuevo Leon, Mexico. Electronic address: fbosques58@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220628
PL  - Mexico
TA  - Rev Gastroenterol Mex (Engl Ed)
JT  - Revista de gastroenterologia de Mexico (English)
JID - 101778603
RN  - 0 (Anti-Bacterial Agents)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Clarithromycin/pharmacology/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/microbiology
MH  - *Helicobacter pylori/genetics
MH  - Humans
OTO - NOTNLM
OT  - Antimicrobial resistance
OT  - Helicobacter pylori
OT  - Molecular methods
OT  - Metodos moleculares
OT  - Resistencia antimicrobiana
OT  - Tratamiento
OT  - Treatment
EDAT- 2022/07/02 06:00
MHDA- 2022/08/04 06:00
CRDT- 2022/07/01 22:15
PHST- 2021/07/27 00:00 [received]
PHST- 2022/01/06 00:00 [accepted]
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/07/01 22:15 [entrez]
AID - S2255-534X(22)00065-2 [pii]
AID - 10.1016/j.rgmxen.2022.06.003 [doi]
PST - ppublish
SO  - Rev Gastroenterol Mex (Engl Ed). 2022 Jul-Sep;87(3):330-341. doi: 
      10.1016/j.rgmxen.2022.06.003. Epub 2022 Jun 28.